Mihály Cserepes - Concepedia

Author

Mihály Cserepes

National Institute of Oncology ORCID

Also Known As

Mihaly Cserepes, Mihaly T. Cserepes, Mihály Cserepes, Mihály T Cserepes, Mihály T. Cserepes, Mihály Tamás Cserepes

Publications

498

Citations

H-Index

Concepts

All Affiliations

National Institute of Oncology Semmelweis University Institute of Molecular Life Sciences Hungarian Academy of Sciences HUN-REN Research Centre for Natural Sciences

About

Mihály Cserepes is an author at National Institute of Oncology specializing in medicine, radiation oncology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	264
2	Cell Biology	2	2	62
3	Health Sciences	1	1	92
4	Allergy	1	1	12
5	Biomolecular Engineering	1	1	16

Mihály Cserepes

Publications

461

Citations

H-Index

Page 1

	Year	Citations
Pegylated liposomal formulation of doxorubicin overcomes drug resistance in a genetically engineered mouse model of breast cancer András Füredi, Kornélia Szebényi, Szilárd Tóth, Journal of Controlled Release Health SciencesPolymer-drug ConjugateMedicineBreast CancerTumor Targeting	2017	92
Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma Zoltán Lohinai, Mir Alireza Hoda, Katalin Fábián, Journal of Thoracic Oncology MedicineLung AdenocarcinomaPathologyBronchial NeoplasmDistinct Epidemiology	2015	82
Subtype-specific KRAS mutations in advanced lung adenocarcinoma: A retrospective study of patients treated with platinum-based chemotherapy Mihály Cserepes, Gyula Ostoros, Zoltán Lohinai, European Journal of Cancer	2014	71
Unshielding Multidrug Resistant Cancer through Selective Iron Depletion of P-Glycoprotein–Expressing Cells Mihály Cserepes, Dóra Türk, Szilárd Tóth, Cancer Research	2019	33
Cell type-dependent HIF1 α-mediated effects of hypoxia on proliferation, migration and metastatic potential of human tumor cells Enikő Tátrai, Alexandra Bartal, Alexandra Gacs, Oncotarget Cancer ResearchTumor HypoxiaHuman Tumor CellsVitro HypoxiaSmall Gtpases	2017	31
Inhibition of epidermal growth factor receptor improves antitumor efficacy of vemurafenib in BRAF-mutant human melanoma in preclinical model István Kenessey, Zsófia Kramer, Lilla István, Melanoma Research PathologyAntitumor EfficacyDermatologyBraf-mutant Human MelanomaTumor Biology	2018	31
Farnesyl-transferase inhibitors show synergistic anticancer effects in combination with novel KRAS-G12C inhibitors Marcell Baranyi, Eszter Molnár, Luca Hegedüs, British Journal of Cancer	2024	26
A user-friendly, high-throughput tool for the precise fluorescent quantification of deoxyribonucleoside triphosphates from biological samples J. Szabó, Éva Viola Surányi, Bence Sándor Mébold, Nucleic Acids Research	2020	23
P38 MAPK Promotes Migration and Metastatic Activity of BRAF Mutant Melanoma Cells by Inducing Degradation of PMCA4b Randa Naffa, Lisa Vogel, Luca Hegedüs, Cells	2020	22
Discovery and development of extreme selective inhibitors of the ITD and D835Y mutant FLT3 kinases Ferenc Baska, Anna Sipos, Zoltán Őrfi, European Journal of Medicinal Chemistry Flt3 KinasesProtein FunctionSignaling PathwayReceptor Tyrosine KinaseMolecular Biology	2019	16

Page 1